• 1.

    Kidney Disease Improving Global Outcomes (KDIGO) Clinical Practice Guideline for anemia in chronic kidney disease. Kidney Int Suppl 2012; 2:292298.

  • 2.

    Besarab A, et al. The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin. N Engl J Med 1998; 339:584590.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 3.

    Drüeke TB, et al. Normalization of hemoglobin level in patients with chronic kidney disease and anemia. N Engl J Med 2006; 355:20712084.

  • 4.

    Singh AK, et al. Correction of anemia with epoetin alfa in chronic kidney disease. N Engl J Med 2006; 355:20852098.

  • 5.

    Pfeffer MA, et al. A trial of darbepoetin alfa in type 2 diabetes and chronic kidney disease. N Engl J Med 2009; 361:20192032.

  • 6.

    Macdougall IC, et al. Intravenous iron in patients undergoing maintenance hemodialysis. N Engl J Med 2019; 380:447458.

  • 7.

    Macdougall IC, et al. Iron management in chronic kidney disease: Conclusions from a “Kidney Disease: Improving Global Outcomes” (KDIGO) controversies conference. Kidney Int 2016; 89:2839.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 8.

    Gupta N, Wish JB. Hypoxia-inducible factor prolyl hydroxylase inhibitors: A potential new treatment for anemia in patients with CKD. Am J Kidney Dis 2017; 69:815826.

    • PubMed
    • Search Google Scholar
    • Export Citation
  • 9.

    Locatelli F, et al. Targeting hypoxia-inducible factors for the treatment of anemia in chronic kidney disease patients. Am J Nephrol 2017; 45:187199.

  • 10.


    • PubMed
    • Export Citation

KDIGO Quo Vadis: Anemia

Iain C. Macdougall Iain C. Macdougall, MD is Consultant Nephrologist and Professor of Clinical Nephrology, Department of Renal Medicine at King’s College Hospital, London, United Kingdom.

Search for other papers by Iain C. Macdougall in
Current site
Google Scholar
Restricted access